Eli Lilly is paying Insilico Medicine $115 million upfront for an AI drug discovery collaboration that could reach $2.75 billion total. That’s a 24x milestone-to-upfront ratio, a structure that says Lilly’s confident but not writing blank checks.
The deal grants Lilly an exclusive worldwide license to oral therapeutics for undisclosed indications. Insilico, based in Hong Kong, uses generative AI across the full drug discovery stack — from target identification through preclinical. Its website recently showed a GLP-1 candidate listed as out-licensed to an unnamed partner, which puts Lilly squarely in frame given its existing obesity franchise.
Insilico isn’t pocketing $2.75 billion; it’s pocketing $115 million guaranteed, then waiting on clinical and commercial triggers that may take a decade to hit. AstraZeneca has signed similar-looking AI discovery pacts in the past two years, and those milestone pools are still unclaimed. Lottery-ticket pricing.
Different week, different company: Takeda is cutting 634 U.S. jobs from its Cambridge HQ as part of a $1.26 billion annual savings plan.
Lilly hasn’t disclosed a timeline for the collaboration’s first milestones.
— Diana Kowalski